Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.

Denys H, Martinez-Mena CL, Martens MT, D'Hondt RG, Graas ML, Evron E, Fried G, Ben-Baruch NE, Vulsteke C, Van Steenberghe MM.

Breast Cancer Res Treat. 2020 Apr 2. doi: 10.1007/s10549-020-05604-7. [Epub ahead of print]

PMID:
32240454
2.

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.

Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH.

Sci Transl Med. 2020 Mar 18;12(535). pii: eaaz8235. doi: 10.1126/scitranslmed.aaz8235.

PMID:
32188726
3.

The nocebo effect and tobacco control-First, do no harm?

De Jaeghere EA, Bouche G, Hoebeke P, Holbrouck PM, Denys HG.

Med Hypotheses. 2020 Feb 10;139:109615. doi: 10.1016/j.mehy.2020.109615. [Epub ahead of print]

PMID:
32078961
4.

Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.

Lippens L, Van Bockstal M, De Jaeghere EA, Tummers P, Makar A, De Geyter S, Van de Vijver K, Hendrix A, Vandecasteele K, Denys H.

Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32893. [Epub ahead of print]

PMID:
32017078
5.

Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.

De Jaeghere EA, Denys HG, De Wever O.

Trends Cancer. 2019 Nov;5(11):704-723. doi: 10.1016/j.trecan.2019.09.009. Epub 2019 Oct 29. Review.

PMID:
31735289
6.

Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.

De Jaeghere EA, Gremonprez FB, Tummers PG, Willaert WC, Ceelen WP, Amant FC, Denys HG.

J Clin Oncol. 2019 Nov 20;37(33):3169-3170. doi: 10.1200/JCO.19.01179. Epub 2019 Sep 25. No abstract available.

PMID:
31553679
7.

The generation and use of recombinant extracellular vesicles as biological reference material.

Geeurickx E, Tulkens J, Dhondt B, Van Deun J, Lippens L, Vergauwen G, Heyrman E, De Sutter D, Gevaert K, Impens F, Miinalainen I, Van Bockstal PJ, De Beer T, Wauben MHM, Nolte-'t-Hoen ENM, Bloch K, Swinnen JV, van der Pol E, Nieuwland R, Braems G, Callewaert N, Mestdagh P, Vandesompele J, Denys H, Eyckerman S, De Wever O, Hendrix A.

Nat Commun. 2019 Jul 23;10(1):3288. doi: 10.1038/s41467-019-11182-0.

8.

The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.

Loret N, Denys H, Tummers P, Berx G.

Cancers (Basel). 2019 Jun 17;11(6). pii: E838. doi: 10.3390/cancers11060838. Review.

9.

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H.

BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3.

10.

Corneal features in trastuzumab emtansine treatment: not a rare occurrence.

Deklerck E, Denys H, Kreps EO.

Breast Cancer Res Treat. 2019 Jun;175(2):525-530. doi: 10.1007/s10549-019-05179-y. Epub 2019 Feb 28.

PMID:
30820718
11.

Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.

Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, De Scheerder MA, Miinalainen I, Rappu P, De Geest BG, Vandecasteele K, Laukens D, Vandekerckhove L, Denys H, Vandesompele J, De Wever O, Hendrix A.

Gut. 2020 Jan;69(1):191-193. doi: 10.1136/gutjnl-2018-317726. Epub 2018 Dec 5. No abstract available.

12.

Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates.

Couvreur K, Naert E, De Jaeghere E, Tummers P, Makar A, De Visschere P, Van Bockstal M, Van Dorpe J, De Neve W, Denys H, Vandecasteele K.

BMC Cancer. 2018 Nov 12;18(1):1101. doi: 10.1186/s12885-018-5007-0.

13.

EXclusion of non-Involved uterus from the Target Volume (EXIT-trial): an individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques.

Vandecasteele K, Tummers P, Van Bockstal M, De Visschere P, Vercauteren T, De Gersem W, Denys H, Naert E, Makar A, De Neve W.

BMC Cancer. 2018 Sep 17;18(1):898. doi: 10.1186/s12885-018-4800-0.

14.

Collagen Alignment and Recurrence of DCIS-Letter.

Libbrecht L, Lambein K, Van Bockstal M, Denys H.

Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):613. doi: 10.1158/1055-9965.EPI-17-1071. No abstract available.

15.

Corneal Changes in Trastuzumab Emtansine Treatment.

Kreps EO, Derveaux T, Denys H.

Clin Breast Cancer. 2018 Aug;18(4):e427-e429. doi: 10.1016/j.clbc.2018.03.005. Epub 2018 Mar 12. No abstract available.

PMID:
29615304
16.

Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research.

Vergauwen G, Dhondt B, Van Deun J, De Smedt E, Berx G, Timmerman E, Gevaert K, Miinalainen I, Cocquyt V, Braems G, Van den Broecke R, Denys H, De Wever O, Hendrix A.

Sci Rep. 2017 Jun 2;7(1):2704. doi: 10.1038/s41598-017-02599-y.

17.

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.

Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.

PMID:
28567637
18.

Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth.

Lapeire L, Hendrix A, Lecoutere E, Van Bockstal M, Vandesompele J, Maynard D, Braems G, Van Den Broecke R, Müller C, Bracke M, Cocquyt V, Denys H, De Wever O.

Oncotarget. 2017 Jul 18;8(29):47239-47249. doi: 10.18632/oncotarget.17592.

19.

The isolation of morphologically intact and biologically active extracellular vesicles from the secretome of cancer-associated adipose tissue.

Jeurissen S, Vergauwen G, Van Deun J, Lapeire L, Depoorter V, Miinalainen I, Sormunen R, Van den Broecke R, Braems G, Cocquyt V, Denys H, Hendrix A.

Cell Adh Migr. 2017 Mar 4;11(2):196-204. doi: 10.1080/19336918.2017.1279784. Epub 2017 Feb 1.

20.

Extraskeletal osteosarcoma of the orbit: A clinicopathologic case report and review of literature.

de Maeyer VM, Kestelyn PA, Shah AD, Van Den Broecke CM, Denys HG, Decock CE.

Indian J Ophthalmol. 2016 Sep;64(9):687-689. doi: 10.4103/0301-4738.97555. Review.

21.

Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.

De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.

Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31. Review.

PMID:
27267353
22.
23.

When fat becomes an ally of the enemy: adipose tissue as collaborator in human breast cancer.

Lapeire L, Denys H, Cocquyt V, De Wever O.

Horm Mol Biol Clin Investig. 2015 Jul;23(1):21-38. doi: 10.1515/hmbci-2015-0018. Review.

PMID:
26154196
24.

Behavioural ecology and group cohesion of juvenile western lowland gorillas (Gorilla g. gorilla) during rehabilitation in the Batéké Plateaux National Park, Gabon.

Le Flohic G, Motsch P, DeNys H, Childs S, Courage A, King T.

PLoS One. 2015 Mar 26;10(3):e0119609. doi: 10.1371/journal.pone.0119609. eCollection 2015.

25.

Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature.

Vertriest C, Berardi G, Tomassini F, Vanden Broucke R, Depypere H, Cocquyt V, Denys H, Van Belle S, Troisi RI.

Dig Surg. 2015;32(1):52-9. doi: 10.1159/000375132. Epub 2015 Feb 11. Review.

PMID:
25675843
26.

Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion.

Van Bockstal M, Lambein K, Van Gele M, De Vlieghere E, Limame R, Braems G, Van den Broecke R, Cocquyt V, Denys H, Bracke M, Libbrecht L, De Wever O.

Oncoscience. 2014 Oct 15;1(10):634-48. eCollection 2014.

27.

Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling.

Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P, Vandesompele J, Vanhove C, Maynard D, Lehuédé C, Muller C, Valet P, Gespach CP, Bracke M, Cocquyt V, Denys H, De Wever O.

Cancer Res. 2014 Dec 1;74(23):6806-19. doi: 10.1158/0008-5472.CAN-14-0160. Epub 2014 Sep 24.

28.

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Van Bockstal M, Lambein K, Denys H, Braems G, Nuyts A, Van den Broecke R, Cocquyt V, De Wever O, Libbrecht L.

Virchows Arch. 2014 Sep;465(3):275-89. doi: 10.1007/s00428-014-1609-3. Epub 2014 Jun 29.

PMID:
24973889
29.

2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.

Lambein K, Van Bockstal M, Denys H, Libbrecht L.

J Clin Oncol. 2014 Jun 10;32(17):1856-7. doi: 10.1200/JCO.2013.54.2530. Epub 2014 Apr 28. No abstract available.

PMID:
24778399
30.

Colloidal stability of nano-sized particles in the peritoneal fluid: towards optimizing drug delivery systems for intraperitoneal therapy.

Dakwar GR, Zagato E, Delanghe J, Hobel S, Aigner A, Denys H, Braeckmans K, Ceelen W, De Smedt SC, Remaut K.

Acta Biomater. 2014 Jul;10(7):2965-75. doi: 10.1016/j.actbio.2014.03.012. Epub 2014 Mar 19.

PMID:
24657672
31.

Evaluation of the quality of the management of cancer of the corpus uteri--selection of relevant quality indicators and implementation in Belgium.

Werbrouck J, Bouche G, de Jonge E, Jacomen G, D'Hondt V, Denys H, Van Limbergen E, Vandermeersch B, De Schutter H, Van Eycken E, Goffin F, Amant F.

Gynecol Oncol. 2013 Dec;131(3):512-9. doi: 10.1016/j.ygyno.2013.10.001. Epub 2013 Oct 6.

PMID:
24103471
32.

Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.

Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, Matthys B, Praet M, Denys H, Libbrecht L.

Am J Clin Pathol. 2013 Oct;140(4):561-6. doi: 10.1309/AJCP4A7KTAYHZSOE.

PMID:
24045554
33.

Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.

Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L.

Histopathology. 2013 Oct;63(4):520-33. doi: 10.1111/his.12188. Epub 2013 Jul 26.

PMID:
23889174
34.

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V.

Springerplus. 2013 May 1;2(1):202. doi: 10.1186/2193-1801-2-202. Print 2013 Dec.

35.

Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results.

Tummers P, Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P, Delrue L, Villeirs G, Lambein K, den Broecke RV.

Int J Gynecol Cancer. 2013 Jun;23(5):877-83. doi: 10.1097/IGC.0b013e31828d1ec0.

PMID:
23698797
36.

Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer.

Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, Braems G, Van den Broecke R, Cocquyt V, Gespach C, Bracke M, De Wever O.

Int J Cancer. 2013 Aug 15;133(4):843-54. doi: 10.1002/ijc.28079. Epub 2013 Mar 7.

37.

Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.

De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, Braems G, Gespach C, Bracke M, De Wever O.

Gut. 2013 Apr;62(4):550-60. doi: 10.1136/gutjnl-2011-301393. Epub 2012 Apr 25.

PMID:
22535374
38.

Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.

Vandecasteele K, Makar A, Van den Broecke R, Delrue L, Denys H, Lambein K, Lambert B, van Eijkeren M, Tummers P, De Meerleer G.

Strahlenther Onkol. 2012 Jul;188(7):576-81. doi: 10.1007/s00066-012-0097-0. Epub 2012 Apr 19.

PMID:
22526231
39.

Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.

Vandecasteele K, Tummers P, Makar A, van Eijkeren M, Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, De Meerleer G.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. doi: 10.1016/j.ijrobp.2011.12.020. Epub 2012 Feb 28.

PMID:
22377596
40.

Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.

Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G.

Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925.

PMID:
22237382
41.

Use of tamoxifen before and during pregnancy.

Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R.

Oncologist. 2011;16(11):1547-51. doi: 10.1634/theoncologist.2011-0121. Epub 2011 Oct 21. Review.

42.

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H.

Acta Clin Belg. 2011 Jan-Feb;66(1):2-9. Review.

PMID:
21485757
43.

Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.

Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B, Cocquyt V, Denys H, Pauwels P, Libbrecht L.

J Clin Pathol. 2011 Mar;64(3):200-7. doi: 10.1136/jcp.2010.084863. Epub 2010 Dec 22.

PMID:
21177747
44.

Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.

Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V.

Acta Clin Belg. 2010 Sep-Oct;65(5):300-4.

PMID:
21128555
45.

Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.

Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V, Gespach C, Bracke M, Seabra MC, Gahl WA, De Wever O, Westbroek W.

J Natl Cancer Inst. 2010 Jun 16;102(12):866-80. doi: 10.1093/jnci/djq153. Epub 2010 May 18.

46.

Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.

De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24.

PMID:
20421155
47.

Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.

Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P.

Ann Surg Oncol. 2012 Jul;19(7):2352-9. doi: 10.1245/s10434-009-0878-6. Epub 2009 Dec 29.

PMID:
20039210
48.

Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva.

Maudens KE, Stove CP, Cocquyt VF, Denys H, Lambert WE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3907-15. doi: 10.1016/j.jchromb.2009.09.044. Epub 2009 Oct 2.

PMID:
19828385
49.

The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment.

Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A, Mathieu V, Bracke M, De Wever O.

Curr Pharm Des. 2009;15(12):1373-84. Review.

PMID:
19355975
50.

Preceding sentinel node biopsy in early breast cancer: does it affect the number of axillary lymph nodes?

Braems G, Denys H, Cocquyt V, Van den Broecke R.

Acta Chir Belg. 2008 Nov-Dec;108(6):691-5.

PMID:
19241919

Supplemental Content

Support Center